Astrazeneca (AZN) Receivables - Other (2021 - 2025)

Astrazeneca's Receivables - Other history runs 5 years deep, the most recent figure standing at $2.0 billion for Q4 2025.

• In Q4 2025, Receivables - Other rose 27.74% year-over-year to $2.0 billion; the TTM figure through Dec 2025 stood at $2.0 billion (up 27.74% YoY), while the FY2025 annual figure was $2.0 billion, up 27.74% from the prior year.
• Receivables - Other was $2.0 billion for Q4 2025 at Astrazeneca, up from $1.6 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $2.0 billion in Q4 2025 to a low of $1.6 billion in Q4 2024.
• Historically, Receivables - Other has averaged $1.7 billion across 5 years, with a median of $1.7 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other slipped 8.24% in 2022, then gained 27.74% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.8 billion in 2021, then slipped by 8.24% to $1.7 billion in 2022, then decreased by 1.21% to $1.6 billion in 2023, then retreated by 3.66% to $1.6 billion in 2024, then gained by 27.74% to $2.0 billion in 2025.
• The last three Receivables - Other figures came in at $2.0 billion (Q4 2025), $1.6 billion (Q4 2024), and $1.6 billion (Q4 2023), per Business Quant data.